Author of

• 20156

  +

  P1.07 - Immunology and Immunotherapy (ID 693)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22712

    +

    P1.07-044 - The Impact of Neutrophil/Lymphocyte Ratio as the Predictive Marker to Anti-PD-1 Antibody Treatment in NSCLC Patients (ID 9913)

    09:30 - 09:30  |  Author(s): Y. Kaneko
    • Abstract

    Background:
    Anti-Programmed death 1 (PD-1) antibody which enhances anti-tumor activity of cytotoxic T lymphocytes by blockade of PD-1/PD-L1 pathway has demonstrated improvement of survival in the patients with advanced non-small-cell lung cancer (NSCLC). PD-1 and its ligand PD-L1 is also known as key players in the formation of tumor microenvironment, closely related with inflammatory cytokines. Here, we retrospectively analyzed the potential of peripheral blood biomarkers for predicting outcome of anti-PD-1 antibody therapy.
    
    Method:
    Patients treated with anti-PD-1 antibody nivolumab from February 2016 to March 2017 in our hospital were selected. We investigated the tendency of differential leukocyte counts and c-reactive protein (CRP) in peripheral blood as inflammatory markers on the treatment progress with nivolumab.
    
    Result:
    19 patients were enrolled. Median age was 67, ECOG-PS 0 or 1 were 16 (84.2%). Histological subtypes were non-squamous 10 (52.6%), and squamous 9 (47.4%). Median follow-up was 7.2 months (range: 2.2-16.1 months), median progression free survival was 2.5 months. Disease control rate was 42.1%, and overall response rate was 26.3%. Of some parameters in peripheral blood, lower absolute lymphocyte count (ALC), higher absolute neutrophil count (ANC), neutrophil to lymphocyte ratio (NLR), and platelet lymphocyte ratio (PLR) at baseline were associated with shorter survival. Interestingly, patient with longer PFS decreased NLR at baseline and its parameter remained at low levels until disease progression.
    
    Conclusion:
    Lower pre-treatment ANC, NLR and PLR are associated with longer survival, and increased NLR during nivolumab therapy is reflect disease progression in NSCLC patients. We suggest that peripheral blood biomarkers may predict response and acquisition of resistance to anti-PD-1 therapy.